An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
暂无分享,去创建一个
M. Whirl‐Carrillo | D. Voora | K. Friede | L. Cavallari | K. Tantisira | K. Crews | F. Aminkeng | S. Tuteja | A. Oni‐Orisan | Christelle Lteif | Glenda Hoffecker | William A. Murphy | Nam H. K. Nguyen | Jasmine A. Luzum | Julio D. Duarte | Yimei Huang | D. M. Smith | Matteo Castrichini | M. Castrichini | Michelle Whirl‐Carrillo
[1] A. Gaedigk,et al. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens , 2023, Clinical pharmacology and therapeutics.
[2] H. Sabbah,et al. Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank. , 2023, Circulation Genomic and Precision Medicine.
[3] M. Pirmohamed,et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study , 2023, The Lancet.
[4] F. Moriarty,et al. Direct-to-consumer genetic testing: an updated systematic review of healthcare professionals’ knowledge and views, and ethical and legal concerns , 2022, European Journal of Human Genetics.
[5] C. Iribarren,et al. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real‐World Population , 2022, Clinical pharmacology and therapeutics.
[6] E. Ashley,et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2022, Circulation.
[7] M. Pirmohamed,et al. Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries , 2022, PloS one.
[8] L. Gong,et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms , 2022, Clinical pharmacology and therapeutics.
[9] M. Farkouh,et al. ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial , 2022, Journal of the American Heart Association.
[10] D. Voora,et al. SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care , 2022, Clinical pharmacology and therapeutics.
[11] Yee Ming Lee,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update , 2022, Clinical pharmacology and therapeutics.
[12] Hao Li,et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. , 2021, The New England journal of medicine.
[13] D. Melzer,et al. Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long‐term outcomes in women and men , 2021, medRxiv.
[14] N. Risch,et al. Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and Atorvastatin , 2021, Clinical pharmacology and therapeutics.
[15] S. V. Van Driest,et al. Moving Pharmacogenetics Into Practice: It’s All About the Evidence! , 2021, Clinical pharmacology and therapeutics.
[16] L. Cavallari,et al. Pharmacogenetics to guide cardiovascular drug therapy , 2021, Nature Reviews Cardiology.
[17] V. Murthy,et al. SEX-BASED DIFFERENCES IN CLINICAL OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TAILOR-PCI TRIAL , 2021 .
[18] D. Stenehjem,et al. Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs. , 2021, Pharmacogenomics.
[19] Ebony B Madden,et al. Establishing the Value of Genomics in Medicine – The IGNITE Pragmatic Trials Network , 2021, Genetics in Medicine.
[20] K. Bailey,et al. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. , 2021, JACC. Cardiovascular interventions.
[21] T. Klein,et al. Expanding evidence leads to new pharmacogenomics payer coverage , 2021, Genetics in Medicine.
[22] G. Tison,et al. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker‐driven precision dosing , 2021, Clinical and translational science.
[23] C. Formea,et al. Considerations When Applying Pharmacogenomics to Your Practice. , 2020, Mayo Clinic proceedings.
[24] Amy L. Pasternak,et al. Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources , 2020, npj Genomic Medicine.
[25] R. Weinshilboum,et al. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? , 2020, Genetics in Medicine.
[26] W. Kraus,et al. Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure , 2020, Circulation. Heart failure.
[27] K. Bailey,et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.
[28] A. Shatnawi,et al. Pharmacogenomics Instruction Depth, Extent, and Perception in US Medical Curricula , 2020, Journal of medical education and curricular development.
[29] Wenwen Du,et al. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin , 2020, European Journal of Clinical Pharmacology.
[30] M. Price,et al. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.
[31] M. Relling,et al. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later , 2019, Clinical pharmacology and therapeutics.
[32] N. Limdi,et al. Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples , 2019, Clinical and translational science.
[33] G. Abecasis,et al. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial , 2019, Circulation.
[34] M. Postma,et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.
[35] K. Caudle,et al. Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists. , 2019, Journal of the American Pharmacists Association : JAPhA.
[36] P. Hulick,et al. Pharmacogenomics: Prescribing Precisely. , 2019, The Medical clinics of North America.
[37] Marco Valgimigli,et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. , 2019, JACC. Cardiovascular interventions.
[38] Weidang Wu,et al. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations , 2019, Asian journal of pharmaceutical sciences.
[39] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[40] Ricardo L. Rojas,et al. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases , 2019, Genetics in Medicine.
[41] N. Khanfar,et al. A comparative study of the depth, breadth, and perception of pharmacogenomics instruction in a subgroup of US pharmacy curricula. , 2019, Currents in pharmacy teaching & learning.
[42] L. Goldstein,et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[43] Kristin A. Maloney,et al. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy , 2018, Clinical pharmacology and therapeutics.
[44] N. Risch,et al. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort , 2018, Circulation. Genomic and precision medicine.
[45] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[46] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[47] M. Hadamitzky,et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.
[48] Jeffrey L. Anderson,et al. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial , 2017, JAMA.
[49] R. Altman,et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems , 2017, Clinical pharmacology and therapeutics.
[50] Michelle E Klein,et al. Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. , 2017, Journal of pharmaceutical sciences.
[51] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update , 2017, Clinical pharmacology and therapeutics.
[52] Mikael Hallstrøm Eriksen,et al. Barriers and solutions , 2017 .
[53] Meenakshi,et al. Complementary feeding at 4 versus 6 months of age for preterm infants born at less than 34 weeks of gestation: a randomised, open-label, multicentre trial , 2017, The Lancet. Global health.
[54] S. Herzig,et al. Nondirected Testing for Inpatients With Severe Liver Injury , 2017, Journal of hospital medicine.
[55] Dermot F. Reilly,et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.
[56] S. Saini,et al. Extensive testing or focused testing of patients with elevated liver enzymes. , 2017, Journal of hepatology.
[57] J. Tenenbaum,et al. Beyond the Genetic Information Nondiscrimination Act: ethical and economic implications of the exclusion of disability, long-term care and life insurance. , 2017, Personalized medicine.
[58] L. Goh,et al. Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation , 2017, PloS one.
[59] S. Johnston,et al. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis , 2017, Circulation.
[60] J. Hoffman,et al. Integrating pharmacogenomics into electronic health records with clinical decision support. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[61] M. Perez,et al. Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association , 2016, Circulation. Cardiovascular genetics.
[62] M. Weale,et al. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? , 2016, The Pharmacogenomics Journal.
[63] L. Dean. Warfarin Therapy and the Genotypes CYP2C9 and VKORC1 , 2016 .
[64] Yuan Ji,et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. , 2016, The Journal of molecular diagnostics : JMD.
[65] M. Luzum,et al. Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. , 2016, Personalized medicine.
[66] S. Vegter,et al. Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature , 2016, PloS one.
[67] Diane Hauser,et al. The IGNITE network: a model for genomic medicine implementation and research , 2015, BMC Medical Genomics.
[68] U. Hofmann,et al. Heritability of metoprolol and torsemide pharmacokinetics , 2015, Clinical pharmacology and therapeutics.
[69] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .
[70] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.
[71] Olle Melander,et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials , 2015, The Lancet.
[72] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[73] R. Kittles,et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans , 2015, Pharmacogenetics and genomics.
[74] M. Fornage,et al. Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. , 2015, Circulation. Cardiovascular genetics.
[75] Teri E Klein,et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.
[76] L Gong,et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.
[77] Anya E. R. Prince,et al. Genetic Information, Non-Discrimination, and Privacy Protections in Genetic Counseling Practice , 2014, Journal of Genetic Counseling.
[78] Munir Pirmohamed,et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .
[79] R. Becker,et al. Pharmacogenetics of Antiplatelet Therapy , 2014, Current Atherosclerosis Reports.
[80] Aniwaa Owusu Obeng,et al. Clinical pharmacogenetics implementation: Approaches, successes, and challenges , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.
[81] R. Califf,et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.
[82] Erica A. Bowton,et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.
[83] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[84] Edward O'Brien,et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial , 2012, The Lancet.
[85] R. Verbrugge,et al. Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.
[86] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.
[87] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.
[88] Russell A. Wilke,et al. Pharmacogenomics: The Genetics of Variable Drug Responses , 2011, Circulation.
[89] A. Morris,et al. Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.
[90] R. Altman,et al. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. , 2010, The Lancet. Oncology.
[91] T. Langaee,et al. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.
[92] G. Ginsburg,et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.
[93] J. Evans. Recreational genomics; what's in it for you? , 2008, Genetics in Medicine.
[94] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[95] F. Schmidt. Meta-Analysis , 2008 .
[96] D. Nebert,et al. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.
[97] H. Price. Past and future , 1990, Nature.
[98] Matthew J. Ferber,et al. Direct‐to‐Consumer Testing 2.0: Emerging Models of Direct‐to‐Consumer Genetic Testing , 2018, Mayo Clinic proceedings.
[99] Louis Valiquette,et al. 10 years later... , 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[100] Russell A. Wilke,et al. Genetics Primer for the General Cardiologist Pharmacogenomics The Genetics of Variable Drug Responses , 2011 .
[101] S. Cohan. It’s All about the Evidence , 2008 .
[102] Abstr Act,et al. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study , 2008 .
[103] W. Kalow. The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future. , 1990, Life sciences.
[104] R. Knight,et al. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. , 1958, American review of tuberculosis.
[105] P. Freedson,et al. Scientific Statement From the American Heart Association Guide to the Assessment of Physical Activity: Clinical and Research Applications: A , 2015 .